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A B S T R A C T 
Spinal cord stimulation provides analgesia through 
electrical stimulation of the dorsal column of the 
spinal cord via electrode leads placed into the 
epidural space. In traditional tonic stimulation, a 
painful sensation is replaced with paraesthesia. Spinal 
cord stimulation is effective in reducing neuropathic 
pain, enhancing function, and improving quality of 
life in different chronic pain conditions. Currently, 
there is most evidence to support its use for failed 
back surgery syndrome when multidisciplinary 
conventional management is unsuccessful. 
Temporary trial leads are inserted in carefully 
selected patients to test their responsiveness prior to 
permanent implantation. Newer neuromodulation 
modalities are now available. These include burst 
stimulation, high-frequency stimulation, and dorsal 
root ganglion stimulation. Results are encouraging 
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Introduction
Neuromodulation involves the use of an advanced 
medical device to alter the activity of the nervous 
system. Spinal cord stimulation (SCS) is a 
neuromodulation technique that reduces pain 
by electrical stimulation of the dorsal column of 
the spinal cord. Electrical leads are placed into 
the epidural space either percutaneously or by 
laminotomy. The electrical leads are then connected 
to a power source, either an implantable pulse 
generator (IPG) or a radiofrequency unit. The IPG 
can be surgically implanted under the skin.1
 A recent study showed that 28.7% of people in 
Hong Kong have chronic pain.2 This can be a major 
reason for reduced psychosocial function, impaired 
quality of life, and increased health care costs.2 
Spinal cord stimulation mainly targets neuropathic 
pain and has limited efficacy for nociceptive pain.1 
Neuropathic pain is common in Hong Kong, 
affecting 9.03% of the total population and 14.7% 
of chronic pain sufferers.2 For some patients, 
severe pain persists despite multidisciplinary 
management. Strong opioids are often prescribed, 
despite their side-effects and lack of good long-
term efficacy.3 For some of these patients, SCS 
offers effective pain relief and consequent improved 
function. The Neuromodulation Appropriateness 
Consensus Committee (NACC) recommends 
use of neuromodulation techniques before long-
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term opioids for neuropathic pain.4 Spinal cord 
stimulation is currently approved by the Food and 
Drug Administration (FDA) for chronic pain of the 
trunk and limbs, low back pain, leg pain, and failed 
back surgery syndrome (FBSS). European guidelines 
also approve the use of SCS for refractory angina 
pectoris and peripheral limb ischaemia.
 More recently, newer neurostimulation 
modalities have been introduced. These include 
high-frequency spinal cord stimulation (HF-SCS), 
burst stimulation, and dorsal root ganglion (DRG) 
stimulation. These techniques may improve efficacy 
and compensate for deficiencies of traditional tonic 
SCS.
Patient selection
Careful patient assessment is required to confirm 
the indication, assess suitability, and exclude contra-
indications. The NACC recommends that SCS be 
considered after conventional multidisciplinary 
management (usually 3-6 months) has failed in 
patients with neuropathic or mixed pain.4,5 Patients 
should have a well-defined, non-cancer, physiological 
cause of pain.4 Contra-indications should be 
excluded. These include systemic or local infection, 
coagulopathy, need for anticoagulant or antiplatelet 
therapy that cannot be temporarily stopped, and 
uncontrolled psychiatric/psychological problems.5 
Depression, anxiety, somatisation, and poor coping 
MEDICAL PRACTICE
to date, and they may provide superior analgesia and 
cover for deficiencies of traditional tonic stimulation. 
Although complications are not uncommon, they 
are rarely life threatening or permanently disabling. 
Nonetheless, device removal is occasionally needed.
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are associated with poorer outcomes following SCS 
implantation so psychological evaluation is advised 
to ensure that there are no uncontrolled psychiatric/
psychological issues.5-7 Unresolved social issues, in 
particular those related to litigation and secondary 
gain, should also be excluded. The patient should 
have a reasonable cognitive ability, reasonable 
expectations, and be motivated to comply with the 
post-implantation rehabilitation programme.
Spinal cord stimulation: technical 
aspects
The SCS device comprises electrode leads, an 
extension cable, a pulse generator, and a programmer. 
Most percutaneous leads have four to 20 electrode 
contacts, and these are introduced into the epidural 
FIG.		Implantation	techniques	of	spinal	cord	stimulation	(courtesy	of	the	Division	of	Pain	Medicine,	Department	of	
Anaesthesiology,	Queen	Mary	Hospital)
(a) Anterior-posterior fluoroscopic image of percutaneous leads placed in the thoracic epidural space. (b) Lateral fluoroscopic image 
of percutaneous leads placed in the thoracic epidural space. (c) The implantable pulse generator and retrograde percutaneous 
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space via an epidural needle. In the percutaneous 
approach, entry of the epidural needle into the 
epidural space is achieved using the loss of resistance 
(LOR) technique with a LOR syringe under X-ray 
guidance. After entry of the needle into the epidural 
space, the electrode leads are advanced to the target 
level under live X-ray screening to stimulate the 
dorsal column (Fig). The electrodes are then placed 
around the midline of the epidural space to avoid 
stimulating the dorsal nerve roots that can result in 
uncomfortable motor responses and dysaesthesia.1 
Usually two electrode leads are placed. The target 
level depends on the area that needs to be stimulated 
(Table1). The final position of the electrode lead is 
adjusted based on patient feedback during the 
procedure to ensure that the area of stimulation 
matches the area of pain. This is called paraesthesia 
mapping. 
 Three parameters are adjusted to provide 
neurostimulation: frequency, amplitude, and pulse 
width. The frequency determines the quality of 
paraesthesia: 50 Hz is most commonly used.1 The 
pulse width affects the size of the area of paraesthesia 
and amplitude affects stimulation intensity.1 A 
trial period where temporary electrode leads are 
inserted for approximately 5 to 7 days is needed to 
determine analgesic efficacy.1 Pain relief of 50% or 
greater is considered a positive trial.5 This should be 
accompanied by a stable level of daily activity and 
use of analgesic drugs. After a successful trial, a 
permanent SCS implant can be placed several weeks 
to 1 month later. In permanent SCS implantation, 
the electrode leads are tunnelled and connected 
to the IPG that is implanted under the skin in the 
gluteal region or lower abdominal area.
Specific pain conditions
Failed back surgery syndrome
Failed back surgery syndrome is present when 
persistent pain (axial back pain and/or radicular 
leg pain) continues despite back surgery. It is the 
most common indication for SCS with level I-II 
evidence supporting the use of traditional tonic SCS 
for managing FBSS.8 In the PROCESS (Prospective 
Randomised Controlled Multicentre trial of the 
Effectiveness of Spinal Cord Stimulation) trial, 
a multicentre randomised controlled trial, SCS 
together with conservative medical management 
was superior to conservative medical management 
alone in reducing leg pain, improving quality of life, 
and enhancing functional capacity in patients with 
FBSS.9 At 12 months, 48% of patients with SCS plus 
medical management obtained 50% or greater leg 
pain reduction versus 18% in those with medical 
management only.9
 A systematic review of cost-effectiveness 
showed that SCS has a higher initial cost, but is 
more cost-effective in the long term compared 
with conventional medical management.10 Such 
stimulation technique is also more cost-effective 
than reoperation.11
Complex regional pain syndrome
Complex regional pain syndrome (CRPS) can cause 
disabling pain and dysfunction of the limbs. In a 
randomised controlled trial to compare SCS plus 
physical therapy with physical therapy alone in the 
treatment of CRPS, patients with SCS had better 
pain control and health-related quality of life.12 In 
those with an implanted SCS, 39% experienced 
‘much improved’ global perceived effect versus only 
6% of control patients.12 At 2 years of follow-up, the 
visual analogue pain scale decreased by 2.1 cm in 
the SCS–plus–physical therapy group, but did not 
change in the physical therapy–only group.13 By 3 
years after implantation, there was no longer any 
significant difference between the groups but 95% 
of patients with an implant would choose to repeat 
the treatment.14 A cost-effective analysis for CRPS 
over a 15-year period indicated that SCS was cost-
effective.15
Refractory angina pectoris and peripheral 
ischaemic limb pain
Spinal cord stimulation can cause vasodilation 
with consequent improved blood flow. This is an 
option in the management of patients with severe 
coronary artery disease and angina and for whom 
revascularisation is unsuitable. It is associated 
with reduced angina attacks, reduced nitrate 
use, and increased exercise duration compared 
with conventional medical management.16 When 
compared with coronary artery bypass grafting, 
patients with SCS achieved similar symptom relief, 
but required more nitrate and had lower exercise 
capacity.17 It has been shown that SCS is cost-
effective for refractory angina.18
 Spinal cord stimulation is also a therapeutic 
option for patients with critical limb ischaemia 
where surgical treatment is not possible. A meta-
TABLE.		A	guide	for	level	of	initial	lead	placement	for	different	
anatomical areas1
Target area in the body Level of electrode lead 
placement
Posterior occipital region C2
Upper extremity C2-C5
Hand C5-C6
Chest wall and angina T1-T4
Thigh and knee T9-T10
Lower leg and ankle T10-T12
Foot T11-L1
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analysis of randomised controlled trials showed 
improved analgesia and limb salvage rates.19
Other conditions
Other chronic pain conditions where SCS may 
be useful include painful diabetic peripheral 
neuropathy, post-herpetic neuralgia, abdominal/
pelvic pain, post-amputation pain, and chest wall 
pain syndromes. Results from a small randomised 
controlled trial indicate better pain relief with 
SCS compared with medical treatment for painful 




Newer neuromodulation modalities have been 
introduced in recent years, and they may further 
improve patient outcomes. These include HF-SCS, 
burst stimulation, and DRG stimulation. The HF-SCS 
and burst stimulation differ in their programming to 
traditional tonic SCS. Traditional tonic SCS delivers 
a consistent set of pulses at a certain amplitude, 
frequency, and pulse width. For tonic SCS, pulse 
width is usually 300-500 µs, amplitude is 2-5 mA, 
and frequency is 30-100 Hz.5,21 Axial back pain, and 
groin and foot pain are areas that are more difficult 
to target with tonic SCS.22 Tonic SCS produces 
paraesthesia to surround and replace the area of pain. 
Some patients, however, find this tingling sensation 
unpleasant. This can be especially problematic with 
change in body position (especially from sitting to 
standing).4 Newer neuromodulation modalities may 
help tackle some of these problems.
Burst stimulation
Burst stimulation provides high-density stimulation 
where groups of high-frequency impulses or ‘bursts’ 
are delivered intermittently at 40 Hz. Within each 
‘burst’, five pulses with a 1-ms pulse width and 1-ms 
spike interval are delivered at a high frequency of 500 
Hz.21 Amplitude is reduced with the aim of providing 
paraesthesia-free stimulation.
 Current evidence regarding burst SCS is 
limited. A small randomised controlled trial showed 
that burst stimulation reduced back and general pain 
more than that of tonic SCS.23 A systematic review, 
however, concluded that there was insufficient 
evidence to support or discourage use of burst SCS 
for chronic back and limb pain.21 Full results of the 
SUNBURST (Success Using Neuromodulation with 
BURST) study, a multicentre randomised controlled 
trial comparing burst SCS with traditional tonic SCS 
in 121 patients, are awaited. The preliminary results 
involving 85 patients followed up at 24 weeks show 
statistically better analgesia with burst stimulation 
(mean difference of 6 mm visual analogue scale 
points), although the clinical significance appears to 
be small.24 Burst SCS was preferred to tonic by 69% 
of patients.24 Burst SCS may provide improved pain 
control (particularly the back) without paraesthesia.
High-frequency stimulation
The HF-SCS provides electrical stimulation at a 
high frequency of 1 kHz to 10 kHz; 10 kHz is most 
frequently used.25 Such therapy ensures paraesthesia-
free stimulation but is not available in Hong Kong. 
Unlike other forms of SCS, lead implantation for 
HF-SCS is based only on anatomical landmarks so 
paraesthesia mapping that requires a patient to be 
woken up from sedation for assessment is avoided. 
Implantation without paraesthesia mapping makes 
the procedure simpler, and duration of surgery is 
more predictable.
 Clinical studies support HF-SCS for back and 
leg pain.26,27 This therapy has been shown to reduce 
back and leg pain, decrease opioid use, and improve 
sleep and functional status.26 A large randomised 
controlled trial, SENZA, compared high-frequency 
10-kHz stimulation with traditional tonic SCS for 
back and leg pain in 198 patients.27 Patients with 
HF-SCS reported significantly better back and leg 
pain relief than those who received tonic SCS.27 At 
24-month follow-up, 76.5% and 72.9% of patients 
with HF-SCS had at least a 50% reduction in back 
pain and leg pain, respectively.28 This reduction of 
pain was significantly higher than that for patients 
using tonic stimulation, where only 49.3% had at least 
a 50% reduction in back pain and leg pain.28 Of note, 
HF-SCS also resulted in better outcomes in terms of 
disability and patient satisfaction, and one third of 
the patients had reduced opioid consumption.27 A 
retrospective study showed that 68% of patients who 
did not receive satisfactory pain relief with tonic SCS 
had a positive HF-SCS trial, suggesting that HF-SCS 
may salvage patients who are not responsive to tonic 
SCS.29 The FDA has labelled HF-SCS at 10 kHz as 
superior to traditional tonic SCS.22
Dorsal root ganglion stimulation
Stimulation of DRG involves insertion of the 
electrode lead into the epidural space and then 
positioning of it into the neural foramen laterally to 
stimulate the DRG.1 While tonic, burst, and HF-SCS 
act on second-order neurons in the spinal cord, 
DRG exerts its effect on the primary afferent level. 
The DRG is especially useful for targeting discrete 
focal areas of pain, such as the groin and foot that 
are difficult to target using other SCS modalities. 
Another advantage of DRG stimulation is a lack 
of change in paraesthesia intensity with change in 
position, possibly due to the stable position of the 
DRG.30
 Clinical studies have shown encouraging 
results for DRG stimulation. A non-comparative 
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study of patients with FBSS, CRPS, and chronic 
post-surgical pain reported overall pain reduction, 
improved mood, and better quality of life with 
DRG stimulation.31 The ACCURATE trial was the 
largest randomised controlled trial to compare 
DRG stimulation against traditional tonic SCS.32 
In 152 patients who had CRPS and/or peripheral 
causalgia of the lower limbs for over 6 months, DRG 
stimulation resulted in better pain control at 3 and 
12 months, greater improvement in quality of life, 
better functional status, and better psychological 
well-being.32 With DRG stimulation, 74.2% of 
patients had over 50% pain reduction at 12 months, 
compared with only 53% of those with traditional 
tonic stimulation.32 The FDA has approved the use 
of DRG stimulation for the treatment of lower-limb 
CRPS.
Complications
The overall safety profile of SCS is good and most 
complications can be reversed by removal of the 
implant. Incidences of complications range from 
30% to 40%, but life-threatening complications are 
rare.33,34
Hardware problems
Notable hardware problems include electrode 
lead migration, lead fracture and malfunction, and 
battery failure. Lead migration is the most common 
complication occurring in 2.1% to 27% of cases, 
with a mean of 15.49%.33 One study showed that it 
was the most common reason for surgical revision 
apart from battery change.35 Lead migration usually 
presents as a change in area of paraesthesia and 
loss of analgesia. Diagnosis can be confirmed with 
X-ray that should show an unintended relocation of 
the lead. Minor lead migrations can be managed by 
reprogramming the stimulator. If this is unsuccessful, 
surgical repositioning is required.
 The incidence of electrode lead fracture ranges 
from 0% to 10.2%, with a mean of 6.37%.33 Lead 
fracture presents as loss of pain relief. X-ray may 
sometimes show the site of fracture. An impedance 
check needs to be performed to diagnose lead 
fracture, and this usually exceeds 4000 ohms.34 The 
fractured lead has to be removed and a new one 
placed.
 Other less common hardware complications 
include battery failure and extension wire failures. 
Battery failure occurs when the battery inside the IPG 
becomes exhausted and requires replacement before 
the expected date; its incidence is around 1.9%.36 
Rarely, extension cable breakage or disconnection 
can occur, and most will require replacement.34
Biological complications
Biological complications include infection, pain, or 
discomfort over device components, dural puncture, 
skin erosion, and neurological injury.
 Infection is a major complication of SCS 
implantation, and a common reason for removal 
of the device. Infection rate ranges from 2.5% to 
14%, with a mean incidence of around 5%.34 Severe 
infection such as epidural abscess is rare. Infection 
involving the subcutaneous IPG pocket is more 
common than infection involving the spinal canal. 
In a review of over 100 cases of infection, 48% were 
caused by staphylococcus and 3% by pseudomonas.37 
Some risk factors included diabetes, debility, 
malnutrition, obesity, a very thin body, autoimmune 
disorders, use of steroids, pre-existing infection, 
poor hygiene, urinary or faecal incontinence, 
malabsorption syndrome, and decubitus ulcers.37
 Clinical symptoms and signs of infection 
include fever, local pain, erythema, swelling, wound 
secretion, and dehiscence. Maintaining a high index 
of clinical suspicion is important for early diagnosis, 
and antibiotic treatment should be started without 
waiting for culture results.37,38 A positive staining 
and/or culture of micro-organisms from the surgical 
wound or implant site confirms the diagnosis. 
Superficial infections may be successfully managed 
with antibiotics alone. Deep infections close to the 
device usually necessitate device removal. Overall, 
treatment of infection without device removal is 
associated with lower success rates, and it is the 
reason most infections ultimately result in device 
removal.37 After infection is controlled, the same 
device can be replaced in an anatomical location 
removed from the site of the infection.34,37 Some 
strategies to reduce risk of infection are listed in the 
Box.34
 Neurological injury is very rare but can occur 
as a result of direct spinal cord injury from needle 
puncture or lead placement. Epidural haematoma 
may rarely develop and lead to delayed neurological 
damage. The incidence of epidural haematoma 
and paralysis has been reported to be 0.3% and 
0.03%, respectively.36 Early surgical consultation 
for exploration and decompression is required if 
epidural haematoma is diagnosed.
Careful patient selection
Pre-surgical bath with antiseptic agent
Antiseptic preparation of surgical sites
Minimising hospital stay
Antibiotic prophylaxis
Surgical implantation under aseptic conditions
Minimising tissue trauma
Avoiding placement of devices directly under incision lines
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 Patients sometimes experience pain around the 
SCS device such as the IPG site. The mean incidence 
is around 6.15%.33 Pain is usually temporary and 
diminishes after 7 to 14 days. Inadvertent dural 
puncture can occur uncommonly during Tuohy 
needle insertion or electrode lead manipulation. The 
rate of dural puncture has been estimated to be 0% 
to 0.3%, and this can result in post-dural puncture 
headache.36 Subcutaneous haematoma or seroma 
may develop, and they most commonly occur in 
the IPG pocket. The IPG pocket may subsequently 
become infected. Aspiration or surgical evacuation 
is occasionally indicated. Skin erosions by leads or 
hardware are rare, with an incidence of only 0.2%.36
Implanter training and mentorship
Appropriate training in SCS implantation is 
essential to ensure optimal outcomes. The NACC 
recommends fellowship training for at least 6 
months, with at least 12 hours of continuing medical 
education directly related to neuromodulation each 
year.5 Those without formal fellowship training 
should perform implantation only after appropriate 
hands-on training with active mentorship.5 During 
formal training, the trainee should perform 10 cases 
under supervision as the primary implanter.5
Practice and challenges in Hong 
Kong
Spinal cord stimulation is considered for 
management of significant chronic pain that is 
refractory to conventional management. It can be 
performed by pain physicians, orthopaedic surgeons, 
or neurosurgeons. A percutaneous approach by pain 
physicians and an open approach via laminotomy 
by surgeons have been performed. Patients typically 
undergo multidisciplinary assessment by the SCS 
surgeon, pain nurses, clinical psychologist, and 
physiotherapists. Suitable patients will undergo a 
trial of SCS and proceed to implant if successful.
 Although SCS has been available for many 
years in other developed countries such as the United 
States, it has only started to attract more interest in 
Hong Kong over the last few years. Few SCS implants 
have been performed and therefore there are little 
local data about its use. Despite the presence of 
local expertise in SCS implantation, there is a lack 
of awareness and familiarity on the part of both 
medical professionals and the general public. This 
means that potentially suitable patients are rarely 
referred for an SCS trial. The cost of an SCS implant 
is around HK$150 000, making it unaffordable for 
many patients. While SCS may be covered by medical 
insurance in some other developed countries, this 
is not the case in Hong Kong. There is also a lack 
of government funding. Education of the general 
public and medical professionals about chronic 
pain management and SCS, as well as financial 
support from the government is imperative in 
order to successfully implement SCS as an effective 
treatment option in Hong Kong. Competent SCS 
implanters who can produce good results are crucial 
to generate support from the government, other 
medical professionals, and the general public.
Conclusion
Spinal cord stimulation provides an effective 
treatment of various chronic pain conditions 
such as FBSS and CRPS. It reduces pain, improves 
function, increases patient satisfaction, improves 
quality of life, and is also cost-effective in the long 
term. The option of SCS should be considered after 
conservative management has failed. Careful patient 
selection and assessment including placement 
of trial leads are required before permanent SCS 
implantation. Newer neuromodulation modalities 
such as burst stimulation, HF-SCS, and DRG 
stimulation are producing promising results. Life-
threatening or debilitating complications are rare. 
Most complications can be reversed with device 
removal. 
Declaration
All authors have disclosed no conflicts of interest.  
References
1. Song JJ, Popescu A, Bell RL. Present and potential use 
of spinal cord stimulation to control chronic pain. Pain 
Physician 2014;17:235-46.
2. Cheung CW, Choi SW, Wong SS, Lee Y, Irwin MG. Changes 
in prevalence, outcomes, and help-seeking behavior of 
chronic pain in an aging population over the last decade. 
Pain Pract 2017;17:643-54.
3. Cheung CW, Chan TC, Chen PP, et al. Opioid therapy for 
chronic non-cancer pain: guidelines for Hong Kong. Hong 
Kong Med J 2016;22:496-505.
4. Deer TR, Mekhail N, Provenzano D, et al. The appropriate 
use of neurostimulation: avoidance and treatment 
of complications of neurostimulation therapies for 
the treatment of chronic pain. Neuromodulation 
Appropriateness Consensus Committee. Neuromodulation 
2014;17:571-97; discussion 597-8.
5. Deer TR, Mekhail N, Provenzano D, et al. The appropriate 
use of neurostimulation of the spinal cord and peripheral 
nervous system for the treatment of chronic pain and 
ischemic diseases: the Neuromodulation Appropriateness 
Consensus Committee. Neuromodulation 2014;17:515-50; 
discussion 550.
6. Celestin J, Edwards RR, Jamison RN. Pretreatment 
psychosocial variables as predictors of outcomes following 
lumbar surgery and spinal cord stimulation: a systematic 
review and literature synthesis. Pain Med 2009;10:639- 
53.
7. Nagel SJ, Lempka SF, Machado AG. Percutaneous spinal 
cord stimulation for chronic pain: indications and patient 
selection. Neurosurg Clin N Am 2014;25:723-33.
8. Grider JS, Manchikanti L, Carayannopoulos A, et al. 
#  Spinal cord stimulation for chronic pain  # 
523Hong Kong Med J  ⎥  Volume 23 Number 5  ⎥  October 2017  ⎥  www.hkmj.org
Effectiveness of spinal cord stimulation in chronic spinal 
pain: a systematic review. Pain Physician 2016;19:E33-54.
9. Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation 
versus conventional medical management for neuropathic 
pain: a multicentre randomised controlled trial in patients 
with failed back surgery syndrome. Pain 2007;132:179-88.
10. Bala MM, Riemsma RP, Nixon J, Kleijnen J. Systematic 
review of the cost-effectiveness of spinal cord stimulation 
for people with failed back surgery syndrome. Clin J Pain 
2008;24:741-56.
11. North RB, Kidd D, Shipley J, Taylor RS. Spinal cord 
stimulation versus reoperation for failed back surgery 
syndrome: a cost effectiveness and cost utility analysis 
based on a randomized, controlled trial. Neurosurgery 
2007;61:361-8; discussion 368-9.
12. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord 
stimulation in patients with chronic reflex sympathetic 
dystrophy. N Engl J Med 2000;343:618-24.
13. Kemler MA, De Vet HC, Barendse GA, Van Den Wildenberg 
FA, Van Kleef M. The effect of spinal cord stimulation in 
patients with chronic reflex sympathetic dystrophy: two 
years’ follow-up of the randomized controlled trial. Ann 
Neurol 2004;55:13-8.
14. Kemler MA, de Vet HC, Barendse GA, van den Wildenberg 
FA, van Kleef M. Effect of spinal cord stimulation for 
chronic complex regional pain syndrome Type I: five-year 
final follow-up of patients in a randomized controlled trial. 
J Neurosurg 2008;108:292-8.
15. Kemler MA, Raphael JH, Bentley A, Taylor RS. The cost-
effectiveness of spinal cord stimulation for complex 
regional pain syndrome. Value Health 2010;13:735-42.
16. Hautvast RW, DeJongste MJ, Staal MJ, van Gilst WH, Lie 
KI. Spinal cord stimulation in chronic intractable angina 
pectoris: a randomized, controlled efficacy study. Am 
Heart J 1998;136:1114-20.
17. Mannheimer C, Eliasson T, Augustinsson LE, et al. 
Electrical stimulation versus coronary artery bypass 
surgery in severe angina pectoris: the ESBY study. 
Circulation 1998;97:1157-63.
18. Kumar K, Rizvi S. Cost-effectiveness of spinal cord 
stimulation therapy in management of chronic pain. Pain 
Med 2013;14:1631-49.
19. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-
reconstructable chronic critical leg ischaemia. Cochrane 
Database Syst Rev 2013;(2):CD004001.
20. Slangen R, Schaper NC, Faber CG, et al. Spinal cord 
stimulation and pain relief in painful diabetic peripheral 
neuropathy: a prospective two-center randomized 
controlled trial. Diabetes Care 2014;37:3016-24.
21. Hou S, Kemp K, Grabois M. A systematic evaluation of 
burst spinal cord stimulation for chronic back and limb 
pain. Neuromodulation 2016;19:398-405.
22. Verrills P, Sinclair C, Barnard A. A review of spinal cord 
stimulation systems for chronic pain. J Pain Res 2016;9:481-
92.
23. De Ridder D, Plazier M, Kamerling N, Menovsky T, 
Vanneste S. Burst spinal cord stimulation for limb and back 
pain. World Neurosurg 2013;80:642-9.e1.
24. Deer TR. SUNBURST Trial Results. Proceedings of the 
19th North American Neuromodulation Society Annual 
Meeting; 2015 Dec 10-13; Las Vegas, USA. 
25. Russo M, Van Buyten JP. 10-kHz high-frequency SCS 
therapy: a clinical summary. Pain Med 2015;16:934-42.
26. AI-Kaisy A, Van Buyten JP, Smet I, Palmisani S, Pang D, 
Smith T. Sustained effectiveness of 10 kHz high-frequency 
spinal cord stimulation for patients with chronic, low back 
pain: 24-month results of a prospective multicenter study. 
Pain Med 2014;15:347-54.
27. Kapural L, Yu C, Doust MW, et al. Novel 10-kHz high-
frequency therapy (HF10 therapy) is superior to traditional 
low-frequency spinal cord stimulation for the treatment of 
chronic back and leg pain: The SENZA-RCT randomized 
controlled trial. Anesthesiology 2015;123:851-60.
28. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz 
high-frequency and traditional low-frequency spinal cord 
stimulation for the treatment of chronic back and leg 
pain: 24-month results from a multicenter, randomized, 
controlled pivotal trial. Neurosurgery 2016;79:667-77.
29. Russo M, Verrills P, Mitchell B, Salmon J, Barnard A, 
Santarelli D. High frequency spinal cord stimulation at 10 
kHz for the treatment of chronic pain: 6-month Australian 
clinical experience. Pain Physician 2016;19:267-80.
30. Kramer J, Liem L, Russo M, Smet I, Van Buyten JP, 
Huygen F. Lack of body positional effects on paresthesias 
when stimulating the dorsal root ganglion (DRG) in the 
treatment of chronic pain. Neuromodulation 2015;18:50-7; 
discussion 57.
31. Liem L, Russo M, Huygen FJ, et al. One-year outcomes of 
spinal cord stimulation of the dorsal root ganglion in the 
treatment of chronic neuropathic pain. Neuromodulation 
2015;18:41-8; discussion 48-9.
32. Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion 
stimulation yielded higher treatment success rate for 
complex regional pain syndrome and causalgia at 3 
and 12 months: a randomized comparative trial. Pain 
2017;158:669-81.
33. Eldabe S, Buchser E, Duarte RV. Complications of spinal 
cord stimulation and peripheral nerve stimulation 
techniques: a review of the literature. Pain Med 
2016;17:325-36.
34. Bendersky D, Yampolsky C. Is spinal cord stimulation 
safe? A review of its complications. World Neurosurg 
2014;82:1359-68.
35. Turner JA, Loeser JD, Deyo RA, Sanders SB. Spinal cord 
stimulation for patients with failed back surgery syndrome 
or complex regional pain syndrome: a systematic review of 
effectiveness and complications. Pain 2004;108:137-47.
36. Cameron T. Safety and efficacy of spinal cord stimulation 
for the treatment of chronic pain: a 20-year literature 
review. J Neurosurg 2004;100(3 Suppl Spine):254-67.
37. Follett KA, Boortz-Marx RL, Drake JM, et al. Prevention 
and management of intrathecal drug delivery and spinal 
cord stimulation system infections. Anesthesiology 
2004;100:1582-94.
38. Rudiger J, Thomson S. Infection rate of spinal cord 
stimulators after a screening trial period. A 53-month 
third party follow-up. Neuromodulation 2011;14:136-41; 
discussion 141.
